Golfyeti, 

Resverlogix has reported post hoc findings that apabetalone elicits increased plasma amyloid beta levels. However, Resverlogix has not reported any evidence of brain amyloid/Alzheimers plaque reversal. Just in case there is confusion, atherosclerotic plaque is not the same as brain amyloid/Alzheimers plaques. Although BETonMACE has a cognition sub study, any positive result will require further clinical trial (probably starting in Phase 2) with a larger Alzheimers patient population and more refined/focused Alzheimers endpoints. Resverlogix presents at the AAIC Alzheimers conference in a couple weeks, so hopefully we hear something new and exciting soon.

BearDownAZ